Next-Generation Oncolytic Virus System for Enhanced Cancer Treatment

Publication ID: 24-11857585_0010_PTD

Published: October 28, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Oncolytic Virus System for Enhanced Cancer Treatment,” Published Technical Disclosure No. 24-11857585_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857585_0010_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,585.

Summary of the Inventive Concept

A revolutionary oncolytic virus system that leverages advanced enzyme engineering, personalized medicine, and cutting-edge diagnostics to selectively target and destroy cancer cells, offering a paradigm shift in cancer treatment.

Background and Problem Solved

Despite the progress made in oncolytic virus research, existing therapies still face limitations in terms of safety, efficacy, and tumor selectivity. The original patent's oncolytic virus, although improved, still relies on a traditional HSV-TK enzyme and lacks personalized targeting capabilities. The new inventive concept addresses these limitations by introducing a next-generation oncolytic virus system that combines advanced enzyme engineering, personalized medicine, and cutting-edge diagnostics.

Detailed Description of the Inventive Concept

The new inventive concept comprises a recombinant oncolytic virus vector that encodes a chimeric HSV-TK enzyme with enhanced substrate specificity for a prodrug, allowing for selective targeting and destruction of cancer cells. The system also includes a method for administering the prodrug to a patient in need thereof. Additionally, the inventive concept encompasses methods for treating cancer using truncated HSV-TK enzyme variants with improved thermal stability, and for detecting cancer cells using radiolabeled prodrugs. Furthermore, the system enables personalized cancer therapy by identifying patient-specific prodrugs based on genetic profiles.

Novelty and Inventive Step

The new claims introduce a paradigm shift in oncolytic virus research by combining advanced enzyme engineering, personalized medicine, and cutting-edge diagnostics. The use of chimeric HSV-TK enzymes, truncated HSV-TK enzyme variants, and radiolabeled prodrugs represents a significant departure from the traditional HSV-TK enzyme used in the original patent. The inventive concept's focus on personalized cancer therapy and advanced diagnostics also sets it apart from existing oncolytic virus therapies.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different viral vectors, such as adenovirus or lentivirus, or the development of novel prodrugs with improved pharmacokinetics. Variations of the system could also include the integration of artificial intelligence or machine learning algorithms to optimize personalized cancer therapy.

Potential Commercial Applications and Market

The next-generation oncolytic virus system has the potential to revolutionize the cancer treatment market, offering a safer, more effective, and personalized approach to cancer therapy. The market for oncolytic virus therapies is expected to grow significantly in the coming years, driven by increasing demand for innovative cancer treatments. The inventive concept's focus on personalized medicine and advanced diagnostics also positions it for success in the rapidly growing precision medicine market.

CPC Classifications

Section	Class	Group
A	A61	A61K35/768
A	A61	A61K9/0019
A	A61	A61K31/708
C	C12	C12N15/86
C	C12	C12N2710/24111

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Molecular virology, cancer therapeutics, and gene therapy, with expertise in viral vector design, enzyme engineering, and targeted cancer treatment strategies

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with advanced degrees in molecular biology or biotechnology, experienced in genetic engineering techniques, oncolytic virus development, and prodrug activation mechanisms

Obviousness Rationale

A person of ordinary skill would recognize that the PTD's variations represent predictable extensions of the source patent's core technology by applying standard enzyme engineering and viral vector modification techniques. The fundamental approach of using HSV-TK enzyme variants for targeted cancer therapy remains consistent, with the PTD merely introducing incremental improvements in substrate specificity, thermal stability, and personalization strategies. These modifications align with established approaches in molecular virology and targeted gene therapy.

Obvious Combinations & Variations

Source Patent Element

Recombinant oncolytic virus with truncated HSV1-TK enzyme fragment

PTD Variation

Chimeric HSV-TK enzyme with enhanced substrate specificity and fusion with tumor-specific antigens

Obviousness Reasoning

A PHOSITA would find it obvious to modify enzyme fragments to improve specificity and targeting, as this represents a standard protein engineering approach with predictable optimization strategies

Source Patent Element

Truncated HSV1-TK enzyme fragments with specific amino acid deletions

PTD Variation

Truncated HSV-TK enzyme variants with improved thermal stability

Obviousness Reasoning

Enzyme stability optimization is a routine technique in protein engineering, with predictable methods for improving protein performance through strategic modifications

Source Patent Element

Oncolytic virus using HSV1-TK for cancer treatment

PTD Variation

Personalized cancer therapy using patient-specific prodrug selection based on genetic profiles

Obviousness Reasoning

Tailoring therapeutic approaches to individual genetic characteristics is a well-established trend in precision medicine, representing an obvious extension of existing targeted therapy concepts

Source Patent Element

Virus-mediated prodrug activation mechanism

PTD Variation

Radiolabeled prodrug detection method for cancer cell identification

Obviousness Reasoning

Expanding diagnostic capabilities through modified prodrug activation is a predictable variation that combines known techniques in molecular imaging and gene therapy

Source Patent Element

Viral vector design for cancer treatment

PTD Variation

Alternative viral vectors like adenovirus or lentivirus with similar HSV-TK mechanisms

Obviousness Reasoning

Exploring alternative viral vector systems is a standard approach in gene therapy, with predictable methods of transferring core therapeutic mechanisms between different viral platforms

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857585 and the disclosed technical variations, a person of ordinary skill in the art would find the claimed innovations obvious and lacking inventive step. The incremental modifications to oncolytic virus design, enzyme engineering, and personalized therapeutic approaches represent predictable extensions of existing knowledge in viral gene therapy, thereby rendering subsequent claims obvious under 35 U.S.C. § 103.

Original Patent Information

Patent Number	US 11,857,585
Title	Oncolytic virus improved in safety and anticancer effect
Assignee(s)	BIONOXX INC.